MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-25-2026
Aptorum Group Limited Total Shareholders Equity 2011-2026 | APM
Annual Total Shareholders Equity Aptorum Group Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.1 M | 21.1 M | 15.4 M | 7.83 M | 17.5 M | 41.8 M | 14.9 M | 33.1 M | 30.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.8 M | 7.83 M | 22.8 M |
Quarterly Total Shareholders Equity Aptorum Group Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 23.6 M | - | 31.5 M | - | 41.8 M | - | 19.8 M | - | 16.4 M | - | 24 M | - | 33.1 M | - | - | - | 30.2 M | - | - | 24.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.8 M | 16.4 M | 27.2 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.83 | -0.96 % | $ 37.9 M |  Israel |
 |
Exelixis
EXEL
|
2.16 B | $ 46.83 | -3.85 % | $ 12.7 B | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 93.78 | -1.55 % | $ 27.2 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Fortress Biotech
FBIO
|
49.9 M | $ 2.48 | -2.94 % | $ 69.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 22.17 | 3.19 % | $ 3.67 B | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.14 | -0.32 % | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.66 | 9.25 % | $ 6.03 M | Israel |
 |
Genprex
GNPX
|
7.96 M | $ 0.89 | -0.2 % | $ 830 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Genmab A/S
GMAB
|
14 B | $ 27.74 | -0.54 % | $ 17.1 B |  Danmark |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 22.41 | -7.3 % | $ 2.85 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-24.2 M | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 53.95 | -2.05 % | $ 4.85 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.63 | -4.41 % | $ 434 M | Britain |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |